Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties

[Image: see text] In our continued effort to discover and develop best-in-class Bruton’s tyrosine kinase (Btk) inhibitors for the treatment of B-cell lymphomas, rheumatoid arthritis, and systemic lupus erythematosus, we devised a series of novel tricyclic compounds that improved upon the druglike pr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ACS Med Chem Lett
Autors principals: Wang, Xiaojing, Barbosa, James, Blomgren, Peter, Bremer, Meire C., Chen, Jacob, Crawford, James J., Deng, Wei, Dong, Liming, Eigenbrot, Charles, Gallion, Steve, Hau, Jonathon, Hu, Huiyong, Johnson, Adam R., Katewa, Arna, Kropf, Jeffrey E., Lee, Seung H., Liu, Lichuan, Lubach, Joseph W., Macaluso, Jen, Maciejewski, Pat, Mitchell, Scott A., Ortwine, Daniel F., DiPaolo, Julie, Reif, Karin, Scheerens, Heleen, Schmitt, Aaron, Wong, Harvey, Xiong, Jin-Ming, Xu, Jianjun, Zhao, Zhongdong, Zhou, Fusheng, Currie, Kevin S., Young, Wendy B.
Format: Artigo
Idioma:Inglês
Publicat: American Chemical Society 2017
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5467183/
https://ncbi.nlm.nih.gov/pubmed/28626519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.7b00103
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars